Larazotide: what it is and what the evidence says
A peptide studied for its relationship with intestinal barrier integrity and epithelial tight junctions.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilising stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Gut health, digestive barrier.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It is one of the few peptides that made it to phase 3 in humans: it had promising phase 2 results in celiac disease, with the best effect at the lowest dose.
The limitation that matters most
The phase 3 trial in celiac disease was halted in 2022 after an interim futility analysis when it failed to beat placebo, and that negative result was never published as an article. The drug is not approved in any country.
Regulatory status
Not approved. Development halted in phase 3.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
A molecule in clinical research for specific conditions; variable individual response.
With diagnosed digestive conditions, professional assessment is essential.
What this page cannot give you
A reference page can take you this far. You know what Larazotide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trialhuman Gastroenterology · 2015 · PMID 25683116 →
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled studyhuman Aliment Pharmacol Ther · 2013 · PMID 23163616 →
- A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challengehuman Am J Gastroenterol · 2012 · PMID 22825365 →
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotidehuman Sci Transl Med · 2025 · PMID 40737433 →
- Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials Clin Res Hepatol Gastroenterol · 2022 · PMID 34339872 →
- Larazotide acetate: a pharmacological peptide approach to tight junction regulationreview Am J Physiol Gastrointest Liver Physiol · 2021 · PMID 33881350 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Larazotide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Larazotide?
A peptide studied for its relationship with intestinal barrier integrity and epithelial tight junctions. It is studied within the area of metabolic.
Is there human evidence for Larazotide?
It is one of the few peptides that made it to phase 3 in humans: it had promising phase 2 results in celiac disease, with the best effect at the lowest dose.
Is it approved by any health agency?
Not approved. Development halted in phase 3.
What is the dose of Larazotide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Larazotide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.